๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Comparison of entecavir and lamivudine in preventing hepatitis B reactivation in lymphoma patients during chemotherapy

โœ Scribed by H.-R. Li; J.-J. Huang; H.-Q. Guo; X. Zhang; Y. Xie; H.-L. Zhu; L.-Z. Zhai; X.-X. Pu; Y. Huang; C.-C. Guo; T.-Y. Lin

Book ID
108886529
Publisher
John Wiley and Sons
Year
2010
Tongue
English
Weight
62 KB
Volume
18
Category
Article
ISSN
1352-0504

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Lamivudine in the treatment of hepatitis
Lamivudine in the treatment of hepatitis B virus reactivation during cytotoxic chemotherapy
โœ Yeo, Winnie; Steinberg, Joyce L.; Tam, John S.; Chan, Paul K.S.; Leung, Nancy W. ๐Ÿ“‚ Article ๐Ÿ“… 1999 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 76 KB ๐Ÿ‘ 2 views

Hepatitis B virus (HBV) reactivation has been described in cancer patients who received cytotoxic/immunosuppressive therapy and may result in liver damage of varying degrees of severity. There is no known effective treatment. Lamivudine, a nucleoside analogue, has been found to suppress HBV replicat

A revisit of prophylactic lamivudine for
A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: A randomized trial
โœ Chiun Hsu; Chao A. Hsiung; Ih-Jen Su; Wei-Shou Hwang; Ming-Chung Wang; Sheng-Fun ๐Ÿ“‚ Article ๐Ÿ“… 2007 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 716 KB

Lamivudine is effective to control hepatitis B virus (HBV) reactivation in HBV-carrying cancer patients who undergo chemotherapy, but the optimal treatment protocol remains undetermined. In this study, HBV carriers with newly diagnosed non-Hodgkin's lymphoma (NHL) who underwent chemotherapy were ran